Skip to main content
james-spicer

Professor James Spicer

Professor of Experimental Cancer Medicine

Research interests

  • Cancer

Contact details

Biography

James Spicer is Professor of Experimental Cancer Medicine within the Comprehensive Cancer Centre. 

    Research

    Novel immunotherapy 780x440
    Cancer Early Phase Trials Unit

    Led by Professor James Spicer, Dr Debashis Sarker and Dr Rebecca Kristeleit, the Cancer Early Phase Trials Unit focuses on the discovery and development of novel molecular and cellular cancer immunotherapies.

    experimental-oncology
    Experimental Oncology

    The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.

    Project status: Ongoing

    Immunology and Immunotherapy Programme Header
    Cancer Immunology & Immunotherapy

    Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.

    Project status: Ongoing

    News

    Trial shows promise for new antibody cancer treatment

    The first ever clinical trial of a new class of immunotherapy for cancer has shown promising results that could benefit patients who do not respond to...

    A person holding white plastic container

    COVID reforms in cancer care and research could have long-term benefits

    A new review led by Professor James Spicer considers the reforms in cancer care and research made due to the pandemic, arguing that some have left a positive...

    cancer care post covid 780×450

    Study shows promising results for immunotherapy targeting skin cancer

    A new class of immunotherapy shows promising results for fighting the most aggressive form of skin cancer.

    Cancer cells

    Experimental cancer treatments receive funding boost

    King's Health Partners (KHP) Experimental Cancer Medicine Centre (ECMC) has had its funding renewed for the next five years.

    Cancer globally

    King's immuno-oncology spin-out gains £30m funding

    A spin-out company created by Professor Sophia Karagiannis and Professor James Spicer has secured £30.75 million to support further development and clinical...

    research lab

    King's immuno-oncology company receives £1 million grant to develop treatments for cancer

    A spin-out company created by Professor Sophia Karagiannis and Professor James Spicer has secured a second Smart Grant of £1 million from the UK’s innovation...

    cancer - main

    New class of immunotherapy drug shows promise in early clinical trial

    Results are disclosed today from the world’s first clinical trial of a new class of immunotherapy drugs which fight cancer using one of the body’s natural...

    immunotherapy cancer trial

    Features

    Transforming cancer care at King's

    King’s is the site of future breakthroughs, transforming cancer care and therapies through innovative research. An injection of philanthropic donations...

    cancer-cells-blue

    Spotlight

    Researchers develop and trial new class of immunotherapy drug to fight cancer

    Immunotherapy works by stimulating the body’s natural defence system to attack cancer.

    drug bottles hero

      Research

      Novel immunotherapy 780x440
      Cancer Early Phase Trials Unit

      Led by Professor James Spicer, Dr Debashis Sarker and Dr Rebecca Kristeleit, the Cancer Early Phase Trials Unit focuses on the discovery and development of novel molecular and cellular cancer immunotherapies.

      experimental-oncology
      Experimental Oncology

      The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.

      Project status: Ongoing

      Immunology and Immunotherapy Programme Header
      Cancer Immunology & Immunotherapy

      Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.

      Project status: Ongoing

      News

      Trial shows promise for new antibody cancer treatment

      The first ever clinical trial of a new class of immunotherapy for cancer has shown promising results that could benefit patients who do not respond to...

      A person holding white plastic container

      COVID reforms in cancer care and research could have long-term benefits

      A new review led by Professor James Spicer considers the reforms in cancer care and research made due to the pandemic, arguing that some have left a positive...

      cancer care post covid 780×450

      Study shows promising results for immunotherapy targeting skin cancer

      A new class of immunotherapy shows promising results for fighting the most aggressive form of skin cancer.

      Cancer cells

      Experimental cancer treatments receive funding boost

      King's Health Partners (KHP) Experimental Cancer Medicine Centre (ECMC) has had its funding renewed for the next five years.

      Cancer globally

      King's immuno-oncology spin-out gains £30m funding

      A spin-out company created by Professor Sophia Karagiannis and Professor James Spicer has secured £30.75 million to support further development and clinical...

      research lab

      King's immuno-oncology company receives £1 million grant to develop treatments for cancer

      A spin-out company created by Professor Sophia Karagiannis and Professor James Spicer has secured a second Smart Grant of £1 million from the UK’s innovation...

      cancer - main

      New class of immunotherapy drug shows promise in early clinical trial

      Results are disclosed today from the world’s first clinical trial of a new class of immunotherapy drugs which fight cancer using one of the body’s natural...

      immunotherapy cancer trial

      Features

      Transforming cancer care at King's

      King’s is the site of future breakthroughs, transforming cancer care and therapies through innovative research. An injection of philanthropic donations...

      cancer-cells-blue

      Spotlight

      Researchers develop and trial new class of immunotherapy drug to fight cancer

      Immunotherapy works by stimulating the body’s natural defence system to attack cancer.

      drug bottles hero